Clinical Trials About "Sutent Drug Insights 2017 Updated 30052017 Prices from" RSS

10:33 EDT 26th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Sutent Drug Insights 2017 Updated 30052017 Prices from" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Sutent Drug Insights 2017 Updated 30052017 Prices from" on BioPortfolio

We have published hundreds of Sutent Drug Insights 2017 Updated 30052017 Prices from news stories on BioPortfolio along with dozens of Sutent Drug Insights 2017 Updated 30052017 Prices from Clinical Trials and PubMed Articles about Sutent Drug Insights 2017 Updated 30052017 Prices from for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sutent Drug Insights 2017 Updated 30052017 Prices from Companies in our database. You can also find out about relevant Sutent Drug Insights 2017 Updated 30052017 Prices from Drugs and Medications on this site too.

Showing "Sutent Drug Insights 2017 Updated 30052017 Prices from" Clinical Trials 1–25 of 4,200+


A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Study Hypothesis: Patients with local renal cell carcinoma who are treated neoadjuvantly with Sutent may show a radiologic response to the study drug (Sutent). The study is looking at the neoadjuvant (pre-surgery) administration of Sutent in patients with localized kidney cancer. The purpose of this research is also to evaluate both the safety and effectiveness of Sutent in this patient population.

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

We are asking patients to take part in this study because they have recurrent (returned) (1st or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM). The purposes of this study are: - To see if Sutent has any change on the patient and their cancer. - To see if Sutent will slow or stop the growth of their tumor. - To measure the safety of Sutent. Sutent is FDA approved to treat patients with a gastrointestinal stromal tumor after the disease...

Sutent Rechallenge In mRCC Patients

Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer

This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited, new therapies are desperately needed. This study is designed to see if Sutent following therapy with radioactive iodine will target cancer cells and delay disease progression better than standard therapy alone. Newly diagnosed patients, who are scheduled...

Study In Patients With Kidney Cancer Treated With Sutent

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Phase II Sunitinib Prog Met AIPC

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®. Secondary objectives: treatment response, hypothyroidism prevalence.The efficacy will be assessed using the Objective Response Rate, Time to Progression based on the RECIST criteria and the ECOG performance data.

A Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent

The Sutent® Observational Study is being proposed to assess the real-world usage patterns and effectiveness and tolerability of treatment of Indian patients with advanced renal cell cancer with Sutent®.

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

There are two drugs involved in this study. Sunitinib (Sutent(R)) is approved by the Food and Drug Administration (FDA) for the treatment of advanced renal cell (kidney) cancer and gastrointestinal stromal tumors. Sunitinib is thought to work by blocking the growth of blood vessels into tumors; reducing the blood supply to tumors can slow their growth and sometimes causes the tumors to shrink. Sirolimus has been approved by the FDA to prevent the body from rejecting organ tr...

Meals-for-Moms: Experimental Grocery Store Study

This is a study about how the price of foods affects food buying choices at the grocery store. The price of foods can have a big impact on what people choose to buy and prices change over time. This study is being done to see how changes in food prices affect what mothers choose for their families.

Food-for-Families: Experimental Grocery Store Study

This is a study about how the price of foods affects buying choices at the grocery store. The price of foods can have a big impact on what people choose to buy and prices change over time. This study is being done to see how changes in food prices affect what mothers choose for their families.

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

This is a Phase II study consisting of 1-3 selective hepatic artery embolizations at approximately 5-week intervals, based on the extent of hepatic involvement with the tumor. Sunitinib malate (Sutent) will be administered on days 1-28 of a 42 day cycle. We believe that Sutent following embolization will significantly improve the duration of your response to treatment. Sutent treatment will be continued until disease progression, or excessive toxicity, or a maximum of eight cyc...

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.

The Efficacy of the Nanit-Insights App in Improving Infant Sleep

The proposed study aims to examine the effectiveness of Nanit-Insights, an app-based intervention for parents who wish to improve their infant's sleep.

Pancreatectomy for NET: External Evaluation of WHO 2017 Grading System

Aim: The aim of this study was to investigate the clinicopathological factors and to evaluate the prognostic accuracy of the new World Health Organization (WHO) 2017 grading system in pancreatic neuroendocrine tumor (PanNET) patients. Methods: Data collected between 1997 and December 2017 were analyzed. Histological grading and staging was based on the WHO 2017 grading system. Outcome after surgery and predictors of overall survival (OS) and disease free survival (DFS) were ev...

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

The investigators want to find out if the treatments used in this study are helpful to patients that are diagnosed with hormone receptor positive metastatic breast cancer. The investigators want to also look at any side effects that could happen while patients are on the study treatments. The investigators want to see if there are any changes that could show us if your cancer is responding to the study treatments.

Temodar and Sutent as Therapy for Melanoma

This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determine if there is clinical benefit as determined by the primary end-point of progression-free survival (PFS) at 6 months and additional secondary endpoints (Phase II).

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied. Primary Objectives: 1. To assess the efficacy of presurgical sunitinib therapy by evaluating time to progression. 2. Toxicities of therapy with sunitinib in RCC in the context of presurgical therapy. Secondary Objectives (Clinical): 1. Response rate...

An Open-Label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be treated until disease progression, pain progression, unacceptable toxicity or death due to any cause. Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individua...

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

This is a prospective pilot study designed to suggest differences in the immunologic response to the seasonal influenza vaccine in people with regular vaccination history compared to those vaccinated less regularly. Participants will receive one dose of the Food and Drug Administration (FDA) approved 2016-2017 seasonal influenza vaccine. Immune system data will be collected at standard time points. The duration of the study for each participant will be approximately 1 month.

Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

In Canada and worldwide there is a need for updated independent real-world comparative effectiveness and safety data related to biologic drugs including biosimilar drugs. Biosimilar drugs hold potential to improve access to needed therapies at reduced cost enabling savings to be reallocated to other needs. However updated real-world evidence on comparative effectiveness and safety of biosimilar drugs is lacking. Investigators aim to demonstrate feasibility of creating network o...

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

This is a single center, Phase Ib study of Sunitinib and RAD001 in patients with advanced RCC. The study design is a phase I interpatient dose-escalation with a dose expansion at the maximum tolerated dose (MTD) in patients with metastatic RCC . In the dose escalation portion, patients will be treated with sunitinib, given in an intermittent schedule (2 weeks of daily dosing followed by one week off drug. RAD001 will be given daily. Escalation of both drugs will occur as tole...

Cardiac Magnetic Resonance Imaging After Cardiac Resynchronization Therapy

This study is evaluating how MRI after CRT can provide key insights regarding LV function, structure, and mechanics resulting from CRT in patients with or without LV scar and inform optimal pacing strategies. The expected accurate and reproducible response assessment with cardiac MRI has important implications for evaluating CRT outcomes in clinical trials, and the insights from the post-CRT MRI promise to improve implementation of CRT.

P3 Ghana Cookstove Study

Background: Despite their potential health and social benefits, adoption and use of improved cookstoves has been low throughout much of the world. Explanations for low adoption rates of these technologies include prices that are not affordable for the target populations, limited opportunities for households to learn about cookstoves through peers, and perceptions that these technologies are not appropriate for local cooking needs. The P3 project employs a novel experimen...

More From BioPortfolio on "Sutent Drug Insights 2017 Updated 30052017 Prices from"

Quick Search